GSK plc

GSK plc EBITDA per Share

The EBITDA per Share of GSK plc (GSK.L) as of Oct 23, 2026 is 1.93 GBP. In the previous year, EBITDA per Share was 1.38 GBP — a change of 39.97% (higher).

EBITDA per Share

1.93GBP

YoY

39.97%

Last updated:

EBITDA per Share of GSK plc is 2025 1.93 GBP. EBITDA per Share of GSK plc was 2024 1.38 GBP. It decreases by 39.97% higher compared to the previous year.

The GSK plc EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
2.02 GBP
Jan 1, 2019
1.95 GBP
Jan 1, 2020
2.05 GBP
Jan 1, 2021
1.70 GBP
Jan 1, 2022
1.66 GBP
Jan 1, 2023
1.72 GBP
Jan 1, 2024
1.38 GBP
Jan 1, 2025
1.93 GBP
The GSK plc EBITDA per Share history
YEAREBITDA per ShareYoY
1.93GBP+39.97%
1.38GBP-19.61%
1.72GBP+3.64%
1.66GBP-2.41%
1.70GBP-17.14%
2.05GBP+4.82%
1.95GBP-3.29%
2.02GBP-1.45%
2.05GBP+17.28%
1.75GBP+50.23%
1.16GBP-9.02%
1.28GBP—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

EBITDA per Share of GSK plc is 1.93 GBP in 2025.

EBITDA per Share of GSK plc changed from 1.38 GBP to 1.93 GBP, representing a 39.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share GSK plc since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — GSK plc

All Key Metrics — GSK plc